Publications by authors named "Editta Baldini"

40Publications

A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."

Lung Cancer 2020 07 24;145:226. Epub 2020 Apr 24.

Department of Medical Oncology, San Luca Hospital, Lucca, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.04.018DOI Listing
July 2020

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Int J Cancer 2020 04 7;146(7):1917-1929. Epub 2019 Aug 7.

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027476PMC
April 2020

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.

World J Clin Oncol 2017 Aug;8(4):320-328

Carmelo Tibaldi, Alice Lunghi, Editta Baldini, Division of Oncology, Department of Oncology, S. Luca Hospital, 55100 Lucca, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v8.i4.320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554875PMC
August 2017

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

J Clin Oncol 2017 Apr 30;35(12):1281-1287. Epub 2017 Jan 30.

Marcello Tiseo, Azienda Ospedaliero-Universitaria, Parma; Luca Boni, Clinical Trials Coordinating Center, Istituto Toscano Tumori, Azienda Ospedaliero-Universitaria Careggi, Firenze; Francesca Ambrosio and Ferdinando Riccardi, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, Napoli; Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Editta Baldini and Carmelo Tibaldi, Ospedale San Luca, Lucca; Saverio Cinieri, Ospedale Perrino, Brindisi; Matteo Brighenti, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona; Francesca Zanelli, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Santa Maria Nuova, Reggio Emilia; Efisio Defraia, Ospedale Businco, Cagliari; Rita Chiari, Azienda Ospedaliero-Universitaria, Perugia; Claudio Dazzi, Ospedale Santa Maria delle Croci, Ravenna; Gianni Michele Turolla, Ospedale Civile Umberto I, Lugo di Romagna; Vito D'Alessandro, IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo; Nicoletta Zilembo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Anna Rita Trolese, Ospedale Mater Salutis di Legnago, Legnago; Francesco Grossi, Azienda Ospedaliera Universitaria San Martino IST-Istituto Nazionale per la Ricerca sul Cancro, Genova; and Andrea Ardizzoni, Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4844DOI Listing
April 2017

Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond.

Front Biosci (Elite Ed) 2016 Jan 1;8:170-80. Epub 2016 Jan 1.

Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

View Article

Download full-text PDF

Source
January 2016

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.

Eur J Cancer 2015 Sep 20;51(14):1874-81. Epub 2015 Jul 20.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.003DOI Listing
September 2015

Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.

World J Gastroenterol 2014 May;20(20):6081-91

Lorenzo Fornaro, Virginia Rotella, Editta Baldini, Division of Medical Oncology, Azienda USL2 Lucca, 55100 Lucca, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v20.i20.6081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033447PMC
May 2014

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.

Hum Pathol 2009 Oct 9;40(10):1408-17. Epub 2009 May 9.

Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa and Pisa University Hospital, Pisa, Italy.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S004681770900045
Publisher Site
http://dx.doi.org/10.1016/j.humpath.2009.02.005DOI Listing
October 2009

Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.

Mol Med Rep 2008 Jan-Feb;1(1):41-3

Oncology Department, S. Chiara University Hospital, I-56132 Pisa, Italy.

View Article

Download full-text PDF

Source
October 2012

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

J Natl Cancer Inst 2005 Dec;97(23):1724-33

Institution of Oncologia Medica, Sperimentazioni Cliniche Controllate Istituto Nazionale per la Ricerca sul Cancro, Genova (PB), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dji398DOI Listing
December 2005

Long-term results of combined-modality therapy for inflammatory breast carcinoma.

Clin Breast Cancer 2004 Dec;5(5):358-63

Division of Medical Oncology, S. Chiara University Hospital, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cbc.2004.n.042DOI Listing
December 2004

[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?].

Suppl Tumori 2004 Jul-Aug;3(4):S79-80

Azienda Ospedaliera Santa Chiara, Pisa.

View Article

Download full-text PDF

Source
July 2004

No consensus on the optimal palliative radiotherapy regimen for people with inoperable non-small-cell lung cancer.

Authors:
Editta Baldini

Cancer Treat Rev 2003 Oct;29(5):445-7

Medical Oncology Department, S.Chiara University-hospital, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0305-7372(03)00166-xDOI Listing
October 2003

Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).

Cancer Chemother Pharmacol 2002 May 17;49 Suppl 1:S25-8. Epub 2002 Apr 17.

U.O. Oncologia Medica Ospedale S. Chiara, via Roma n.67, 56100 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-002-0449-zDOI Listing
May 2002

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.

Br J Clin Pharmacol 2002 May;53(5):508-18

Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma 55, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874362PMC
http://dx.doi.org/10.1046/j.1365-2125.2002.01579.xDOI Listing
May 2002